CTKB
Cytek BioSciences Inc

321
Mkt Cap
$635.49M
Volume
1.25M
52W High
$7.30
52W Low
$2.37
PE Ratio
-49.16
CTKB Fundamentals
Price
$4.86
Prev Close
$4.97
Open
$5.00
50D MA
$4.59
Beta
1.37
Avg. Volume
1.93M
EPS (Annual)
-$0.0461
P/B
1.68
Rev/Employee
$309,341.05
Loading...
Loading...
News
all
press releases
Cytek Biosciences (NASDAQ:CTKB) Stock Price Up 7.2% - Here's What Happened
Cytek Biosciences (NASDAQ:CTKB) Trading 7.2% Higher - Time to Buy...
MarketBeat·20d ago
News Placeholder
More News
News Placeholder
Cytek Biosciences (NASDAQ:CTKB) Sees Unusually-High Trading Volume - Time to Buy?
Cytek Biosciences (NASDAQ:CTKB) Sees Large Volume Increase - Here's Why...
MarketBeat·24d ago
News Placeholder
Cytek Biosciences (NASDAQ:CTKB) Shares Gap Up - Time to Buy?
Cytek Biosciences (NASDAQ:CTKB) Shares Gap Up - Here's What Happened...
MarketBeat·27d ago
News Placeholder
Cytek Biosciences (NASDAQ:CTKB) Price Target Lowered to $7.50 at Piper Sandler
Piper Sandler dropped their target price on Cytek Biosciences from $8.00 to $7.50 and set an "overweight" rating on the stock in a research report on Tuesday...
MarketBeat·1mo ago
News Placeholder
Cytek Biosciences (NASDAQ:CTKB) Trading Up 19.3% - Here's What Happened
Cytek Biosciences (NASDAQ:CTKB) Trading Up 19.3% - Here's What Happened...
MarketBeat·1mo ago
News Placeholder
Cytek Biosciences (NASDAQ:CTKB) Announces Quarterly Earnings Results
Cytek Biosciences (NASDAQ:CTKB - Get Free Report) issued its earnings results on Wednesday. The company reported ($0.04) EPS for the quarter, missing the consensus estimate of $0.01 by ($0.05). The...
MarketBeat·1mo ago
News Placeholder
Cytek Biosciences, Inc. (CTKB) Reports Q3 Loss, Tops Revenue Estimates
Cytek Biosciences (CTKB) delivered earnings and revenue surprises of -200.00% and +1.70%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
Alvotech (ALVO) Surges 8.6%: Is This an Indication of Further Gains?
Alvotech (ALVO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Zacks·3mo ago
News Placeholder
Cytek Biosciences, Inc. (CTKB) Beats Q2 Earnings Estimates
Cytek Biosciences (CTKB) delivered earnings and revenue surprises of +150.00% and -3.30%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·4mo ago
News Placeholder
Cytek Biosciences, Inc. (CTKB) Reports Q1 Loss, Lags Revenue Estimates
chainwire·7mo ago

Latest CTKB News

View

Advertisement|Remove ads.

Advertisement|Remove ads.